Abstract
The expression of CYP27B1 or vitamin D 1α-hydroxylase (1α-OHase) and CYP24A1 in specific tissues may act as the central part between 25-hydroxyvitamin D [25(OH)D] serum levels and the anticancer effects of1α,25-dihydroxyvitamin D [1α,25(OH)2D3],alternative splicing of these enzymes may affect their biological functions. Here, we describe the expression of CYP24A1 and its splicing variants detected in breast cells and tissues.
Manifestation of CYP24A1 mRNA was measured by RT-PCR followed by western blot analysis for protein expression.
In MCF-7 cells, the expression of CYP24A1 protein was reduced by about 57% compared to MCF-10F cells. Western blot analysis revealed a signal band at 56 kDa, with additional bands detected at 42 and 44 kDa.
The expression of CYP24A1 mRNA was reduced by about 58% in breast cancer tissues. We found only one signal in the benign tissues at 56 kDa in western blot, whereas in malignant tissue, an additional band was detected at 40kDa.
Our results suggest that alternative splicing of CYP24A1 may lead to a catalytically dysfunctional enzyme.
Keywords: Vitamin D3, 24-hydroxylase, splicing variants, MCF-7, MCF-10, breast tissue.
Anti-Cancer Agents in Medicinal Chemistry
Title:Implication of CYP24A1 Splicing in Breast Cancer
Volume: 14 Issue: 1
Author(s): Chimi Scheible, Marc Thill, Sascha Baum, Erich Solomayer and Michael Friedrich
Affiliation:
Keywords: Vitamin D3, 24-hydroxylase, splicing variants, MCF-7, MCF-10, breast tissue.
Abstract: The expression of CYP27B1 or vitamin D 1α-hydroxylase (1α-OHase) and CYP24A1 in specific tissues may act as the central part between 25-hydroxyvitamin D [25(OH)D] serum levels and the anticancer effects of1α,25-dihydroxyvitamin D [1α,25(OH)2D3],alternative splicing of these enzymes may affect their biological functions. Here, we describe the expression of CYP24A1 and its splicing variants detected in breast cells and tissues.
Manifestation of CYP24A1 mRNA was measured by RT-PCR followed by western blot analysis for protein expression.
In MCF-7 cells, the expression of CYP24A1 protein was reduced by about 57% compared to MCF-10F cells. Western blot analysis revealed a signal band at 56 kDa, with additional bands detected at 42 and 44 kDa.
The expression of CYP24A1 mRNA was reduced by about 58% in breast cancer tissues. We found only one signal in the benign tissues at 56 kDa in western blot, whereas in malignant tissue, an additional band was detected at 40kDa.
Our results suggest that alternative splicing of CYP24A1 may lead to a catalytically dysfunctional enzyme.
Export Options
About this article
Cite this article as:
Scheible Chimi, Thill Marc, Baum Sascha, Solomayer Erich and Friedrich Michael, Implication of CYP24A1 Splicing in Breast Cancer, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (1) . https://dx.doi.org/10.2174/18715206113139990311
DOI https://dx.doi.org/10.2174/18715206113139990311 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Probenecid: An Emerging Tool for Neuroprotection
CNS & Neurological Disorders - Drug Targets Endometrial Cancer as a Familial Tumor: Pathology and Molecular Carcinogenesis (Review)
Current Genomics Biotechnological Engineering of Heparin/Heparan Sulphate: A Novel Area of Multi-Target Drug Discovery
Current Pharmaceutical Design Immunomodulatory Role of Arsenic in Regulatory T Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets A Hypothesis for the Relationship between Depression and Cancer: Role of Ca2+/cAMP Signalling
Anti-Cancer Agents in Medicinal Chemistry Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease
Current Stem Cell Research & Therapy Interaction of ABC Multidrug Transporters with Anticancer Protein Kinase Inhibitors: Substrates and/or Inhibitors?
Current Cancer Drug Targets A Simple and Sensitive LC-MS/MS Method for the Simultaneous Determination of Cyclophosphamide and Doxorubicin Concentrations in Human Plasma
Current Pharmaceutical Analysis Biomedical Applications of Gold Nanoparticles
Current Topics in Medicinal Chemistry Radioprotective Gene Therapy
Current Gene Therapy B Cell Responses to Oxidative Stress
Current Pharmaceutical Design Flavonoids as Anticancer Agents: Structure-Activity Relationship Study
Current Medicinal Chemistry - Anti-Cancer Agents circEPSTI1 Acts as a ceRNA to Regulate the Progression of Osteosarcoma
Current Cancer Drug Targets Intraperitoneal Oncolytic and Tumor Vaccination Therapy with Replication-Competent Recombinant Virus: The Herpes Paradigm
Current Gene Therapy Lifelong and Prenatal Effects of Phytoestrogens
Current Bioactive Compounds Mechanisms of Immune Modulation by Mesenchymal Stromal Cells and Clinical Translation
Current Molecular Medicine Editorial (Thematic Issue: Novel Methods and Tools of the Computational Systems Biology in Bioinformatics and Biomedical Informatics)
Current Bioinformatics A Novel Naphthotriazolyl-4-oxoquinoline Derivative that Selectively Controls Breast Cancer Cells Survival Through the Induction of Apoptosis
Current Topics in Medicinal Chemistry Cyclin Dependent Kinase 1 Inhibitors: A Review of Recent Progress
Current Medicinal Chemistry Tuberculosis Treated by Multiple Drugs: An Overview
Current Drug Delivery